High-density lipoprotein (HDL) mediates reverse cholesterol transport and is known to be protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that may be critical for protection against other inflammatory diseases. The molecular mechanisms of how HDL can modulate inflammation, particularly in immune cells such as macrophages, remain poorly understood. Here we identify the transcriptional regulator ATF3, as an HDL-inducible target gene in macrophages that downregulates the expression of Toll-like receptor (TLR)-induced proinflammatory cytokines. The protective effects of HDL against TLR-induced inflammation were fully dependent on ATF3 in vitro and in vivo. Our findings may explain the broad anti-inflammatory and metabolic actions of HDL and provide the basis for predicting the success of new HDL-based therapies.
The innate immune system uses several families of signaling receptors to detect invading pathogens or tissue damage 1 . Although an appropriate inflammatory response is critical for clearing pathogens and maintaining tissue integrity, excessive or prolonged inflammation can lead to harmful systemic inflammation and organ dysfunction. However, multiple regulatory mechanisms have evolved to limit the extent and duration of the inflammatory response. For instance, activation of TLRs leads to expression of proinflammatory cytokines and also induces expression of many negative regulators, which limit signal transduction, mRNA transcription or translation 2 . Of these, ATF3 is a key inducible transcriptional regulator, which binds to CREB-ATF binding sites in promoters of specific target genes, resulting in chromatin remodeling and subsequent inhibition of transcription-factor binding 3 . ATF3 is induced by TLR stimulation as well as a multitude of other stimuli 4 and acts in a negative-feedback system to limit excessive production of proinflammatory cytokines including TNF, IL-6 and IL-12p40 (refs. 3,5) . Understanding how these regulatory pathways function in the context of chronic inflammatory disease is of great interest and may lead to the design of beneficial therapeutics.
Atherosclerosis is the chronic inflammatory condition underlying coronary artery disease and is driven in part via the recognition of metabolic danger signals by innate immune receptors on macrophages 6, 7 . Elevated levels of HDL cholesterol are associated with reduced atherothrombotic events 8 . Furthermore, studies in animals have shown HDL to be beneficial on the key cell types and processes in atherosclerosis, in part by mediating the removal of cholesterol from lipid-laden macrophages (known as foam cells) 9 . However, therapies based on simply increasing amounts of HDL have been largely unsuccessful 10, 11 , prompting the suggestion that the functionality of HDL may be more important to disease outcome than the quantity of HDL itself 12 . Indeed, cholesterol efflux capacity is better correlated with disease risk than the total amount of HDL cholesterol 13 . HDL also has antioxidant, antithrombotic and anti-inflammatory properties, which may also protect against atherogenesis [14] [15] [16] . The anti-inflammatory nature of HDL could also be beneficial in other inflammatory diseases: it can lower expression of endothelial cell vascular cell adhesion molecule 1 (VCAM-1), increase production of endothelial nitric oxide synthase (eNOS) and reduce expression of monocyte CD11b and migration along a gradient of CCL2 (monocyte chemotactic protein-1; MCP-1) 17 . However, the molecular mechanisms by which HDL mediates its anti-inflammatory functions, especially in macrophages and outside of the context of atherosclerosis, remain poorly understood. We therefore investigated the effects of HDL on activation of macrophages by TLRs and in macrophage-dependent models of inflammation under normocholesterolemic conditions. Here we show that HDL inhibits TLR-induced production of proinflammatory cytokines from macrophages. These effects were independent of HDL binding TLR ligands and did not involve modulation of TLR signaling events or disruption of cytokine secretory processes. Rather, in a time-dependent manner, HDL suppressed the ability of TLRs to induce the expression of proinflammatory cytokines (such as IL-6, IL-12p40 and TNF) on the transcriptional level. Using a systems biology approach, we identified ATF3 as an HDL-inducible negative regulator of macrophage activation. Transcriptome analysis revealed that HDL regulated many genes in an ATF3-dependent manner, and ATF3 chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) confirmed that several key proinflammatory genes were directly targeted by ATF3 after its induction by HDL. Furthermore, the ability of HDL to reduce TLR responses was fully dependent on expression of ATF3 both in vitro and in vivo, demonstrating the critical role of this transcriptional modulator in the anti-inflammatory effects of HDL.
RESULTS

HDL is protective against TLR-induced inflammation
HDL has multiple functions beyond promoting the efflux of cholesterol from lipid-laden cells. To study the anti-inflammatory effects of HDL under normocholesterolemic conditions, we used a well-established in vivo model of acute inflammation, in which the systemic release of proinflammatory cytokines from TLR-activated macrophages leads to liver damage 18, 19 . We injected mice with HDL freshly isolated from patients ('native HDL') or with purified human apolipoprotein A1 (ApoAI; the major protein component of HDL) reconstituted with phospholipids (referred to hereafter as 'HDL') and subsequently challenged the mice with TLR agonists. Pretreatment with either native HDL or HDL significantly reduced liver damage induced by the TLR9 activator CpG DNA, as measured by release of alanine aminotransferase (ALT) or hepatocyte cell death (Fig. 1a-c and data not shown). In addition, mice injected with CpG after pretreatment with native HDL displayed significantly reduced serum levels of the proinflammatory cytokines IL-6 and IL-12p40 (Fig. 1a) . Similarly, mice pretreated with HDL showed reduced serum concentrations of CpG-induced IL-6, IL-12p40, TNF, MCP-1 and IL-10 ( Fig. 1b) , whereas IL-18 and IL-13 remained unaffected ( Supplementary  Fig. 1a ). In addition, HDL pretreatment significantly reduced liver damage and inflammation mediated by the TLR1 and TLR2 ligand, synthetic lipopeptide Pam 3 CSK 4 ( Fig. 1d) . We further investigated the anti-inflammatory effect of HDL in vitro using bone marrow-derived macrophages (BMDMs). Pretreatment of BMDMs with HDL substantially reduced IL-6 and TNF cytokine output in response to a variety of TLR ligands (Fig. 1e) , without impacting cell viability (Fig. 1f) . HDL reduced TLR-mediated production of cytokines in a dose-dependent manner (Supplementary Fig. 1b) . Using enzyme-linked immunosorbent assay (ELISA), we observed comparable decreases in TLR-induced production of IL-6 after pretreatment of BMDMs with native HDL (Fig. 1g) . The capability Figure 1 HDL inhibits TLR-induced cytokine production from macrophages in vivo and in vitro. (a-d) Serum cytokines and ALT amounts (international units/kiloliter) measured 1 h and 10 h, respectively, after mice were injected intraperitoneally (i.p.) with 2 mg HDL for 6 h before injection of TLR ligand (i.p.; 20 µg CpG or 2 µg Pam 3 CSK 4 (P3C)) and 10 mg d-galactosamine. In a, C3H/HeJ mice were injected with native HDL and CpG: ALT release (n = 12 mice per group) and serum cytokines (CpG, n = 28 mice per group; native HDL + CpG, n = 27 mice per group) were measured. In b,c C57BL/6 mice were injected with HDL and CpG; ALT release (n = 9 mice per group) and serum cytokines (CpG, n = 18 mice per group; HDL + CpG, n = 19 mice per group) were measured (b), and liver histology was assayed by hemotoxylin and eosin staining 10 h after injection (c; scale bars, 100 µm). In d, C57BL/6 mice were injected with HDL and P3C: ALT release (n = 15 mice per group) and serum cytokines (n = 15 mice per group) were measured. (e) ELISA of IL-6, IL-12p40 and TNF secretion from BMDMs treated with 2 mg/ml HDL or medium alone (−) for 6 h followed by overnight stimulation with the TLR4 ligand LPS (100 ng/ml), TLR9 ligand CpG (100 nM), TLR7/8 ligand R848 (5 ng/ml) or TLR2/1 ligand P3C (50 ng/ml) or cells were left untreated (UT). (f) Cell viability of BMDMs treated overnight with 2 mg/ml HDL or medium alone (−). (g) ELISA of IL-6 secretion from BMDMs pretreated with medium alone (−), HDL or native HDL (2 mg/ml) for 6 h and stimulated overnight with 100 nM CpG or 50 ng/ml P3C. Data are from one experiment (a,b,d; each symbol represents an individual mouse; horizontal lines indicate mean values TLR ligand versus HDL + TLR ligand, unpaired two-tailed Student's t test; *P < 0.05, **P < 0.01, ***P < 0.005), representative of three mice examined per treatment, with the shown images from single mice exhibiting median expression of ALT (c), and combined from three independent experiments (e,f,g; mean + s.e.m.).
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VOLUME 15 NUMBER 2 FEBRUARY 2014 nature immunology A r t i c l e s of HDL to decrease TLR-induced inflammation was also evident in human peripheral blood mononuclear cells (Supplementary Fig. 1c) . Collectively, these data suggest HDL protects against TLR-induced inflammation by downmodulating the production of proinflammatory cytokines in monocytes and macrophages.
HDL regulates inflammation at the transcriptional level HDL can directly neutralize the inflammatory activity of the TLR4 ligand lipopolysaccharide (LPS) [20] [21] [22] . To examine whether HDL neutralizes other TLR activators by direct interaction, we analyzed whether HDL can change the size-exclusion profile of fluorescent TLR agonists. As expected, HDL led to a shift of LPS-BODIPY into the higher-molecular-weight HDL fractions (Fig. 2a) (Fig. 2b) . In contrast, HDL co-treatment abolished LPS-induced p38 activation (Fig. 2b) . These data suggest that while HDL can attenuate LPS-induced inflammation by sequestration, they do not explain the anti-inflammatory effects of HDL on other TLR ligands, including CpG and Pam 3 CSK 4 .
HDL promotes the efflux of cholesterol from macrophages and thus, subsequent TLR activation might be inhibited via changes to lipid raft cholesterol content 23, 24 . However, whereas pretreatment of BMDMs with HDL decreased cellular cholesterol concentration ( Fig. 2c and Supplementary Fig. 2a) , it did not inhibit CpG-induced signaling, including activation of p38 MAP kinase, Jnk kinase and p65 subunit of the transcription factor NF-κB, or degradation of the inhibitory cytoplasmic NF-κB chaperone IκBα (Fig. 2d) . Furthermore, pretreatment with HDL had no effect on the nuclear translocation of 
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A r t i c l e s NF-κB ( Fig. 2e) nor did it prevent binding of NF-κB to target DNA sequences (Fig. 2f ). Together these data exclude the possibility of interference with early TLR signaling mechanisms. To assess whether HDL affects secretion of cytokines, we measured cytokines in intracellular compartments. Although pretreatment with HDL had no effect on the activation of the p65 subunit of NF-κB in response to stimulation of TLRs, intracellular cytokine expression was diminished in BMDMs pretreated with HDL ( Fig. 2g) , as was the amount of secreted cytokines ( Fig. 2h and Supplementary Fig. 2b,c) . These data suggest that HDL interferes with production but not secretion of cytokines. Consistent with this hypothesis, relative expression of mRNA encoding proinflammatory cytokines was notably reduced when we treated BMDMs with HDL or native HDL before stimulation with CpG ( Fig. 2i and Supplementary Fig. 2d ). Cytokine mRNA expression was also decreased in the livers of mice injected with HDL or native HDL before stimulation with CpG ( Fig. 2j and Supplementary Fig. 2e ). We next assessed whether HDL affects the half-life of TLR-induced cytokine mRNA or protein. Pretreatment of BMDMs with HDL did not alter the stability of Il6 mRNA (Supplementary Fig. 2f ) nor the stability of IL-1β protein (Supplementary Fig. 2g ). Together these data indicate that HDL may regulate anti-inflammatory effects in macrophages by downmodulating transcription of proinflammatory genes.
ATF3 is identified as a candidate transcription factor
We noted that macrophages exposed to HDL for longer periods of time displayed a more pronounced reduction in the production of cytokines (Fig. 3a) , which persisted up to 24 h after removal of HDL (Fig. 3b) . This suggested that the underlying molecular mechanism might involve de novo transcription of an inflammatory repressor. We therefore used genome-wide RNA profiling to assess whether HDL affected the transcriptional response to TLR stimulation, by comparing resting BMDMs with HDL-pretreated BMDMs that we subsequently stimulated with CpG. Principle component analysis and hierarchical clustering indicated that HDL induced profound transcriptional changes in resting and CpG-treated BMDMs (Supplementary Fig. 3a,b) . As expected, treatment with HDL alone induced the gene expression of several enzymes involved in the cholesterol biosynthesis pathway (Supplementary Fig. 3c ). This finding correlated with an increased appearance of cholesterol precursors after treatment with HDL, as identified by mass spectrometry analysis (Supplementary Fig. 3d ). Stimulation of BMDMs with CpG resulted in regulation of 1,135 genes in total, 419 of which were not influenced by pretreatment with HDL ( Fig. 3c,d) . The remaining 716 CpGregulated genes (Fig. 3c) were also regulated by CpG in the presence of HDL relative to resting cells. However, HDL further enhanced or reduced the expression of many of these genes (Fig. 3d) . HDL treatment also modulated the expression of 423 genes (250 induced and 173 repressed) independently of CpG treatment (Fig. 3c,d ). To identify a potential transcription factor that might be responsible for the anti-inflammatory effects of HDL, we interrogated our transcriptome data using several bioinformatics approaches. First, we performed Gene Ontology enrichment analysis (GOEA) using the genes that were regulated by CpG and further modified by HDL and visualized this as a GO term network (Supplementary Fig. 3e ). This analysis identified one subnet, based on genes downregulated by HDL, that could be summarized as 'innate immune response'-related processes, and another large subnet, based on genes induced by HDL, that was linked to cholesterol and lipid metabolism. However, a group of GO terms with the highest enrichment scores were linked to a central dense subnet best summarized as 'regulation of metabolic processes' . Based on this pronounced enrichment of regulatory processes we searched for candidates of transcriptional regulation in this subnet and identified the transcriptional regulator ATF3 in most of the subnet's GO terms (Supplementary Fig. 3e ). Second, using the transcription factor (TF) catalog database (TFCat database) 25 , we identified ATF3 as the TF with the highest expression in the presence of HDL (Fig. 3e) . Finally, we performed TF promoter-binding prediction using the genes most significantly repressed by HDL as bait (fold change < −3, false discovery rate (FDR)-corrected P < 0.05, two-way analysis of variance (ANOVA), n = 33 genes; (Online Methods and Supplementary Fig. 3f ). Table 1 ). Collectively, these analyses strongly support a model in which HDL leads to the repression of CpG-induced genes by increasing the expression of the transcriptional regulator ATF3.
ATF3 binds target gene promoters after HDL induction
Consistent with our transcriptome analysis, BMDMs treated with HDL displayed increased expression of Atf3 mRNA and ATF3 protein in a time-dependent manner (Fig. 4a,b) . The induction of Atf3 mRNA and ATF3 protein by HDL was further potentiated by subsequent stimulation with CpG or Pam 3 CSK 4 (Fig. 4c,d) . Native HDL also induced Atf3 mRNA expression to comparable levels in BMDMs (Fig. 4e) . Additionally, treatment with HDL increased amounts of ATF3 mRNA and ATF3 protein in human monocytes (Fig. 4f,g ). In vivo, HDL injection increased hepatic Atf3 mRNA expression in C57BL/6 mice ( Fig. 4h) , specifically in Kupffer cells (the resident macrophages of the liver; Fig. 4i ). To analyze whether HDL treatment would modulate ATF3 binding to target gene promoters, we performed ATF3 ChIPseq on wild-type and Atf3-deficient BMDMs. We used signals from Atf3-deficient BMDMs to subtract background nonspecific binding of the ATF3 antibody. HDL treatment, either alone or in combination with CpG treatment, dramatically increased ATF3 binding across the genome, whereas CpG treatment alone reduced ATF3 binding (Fig. 5a ). Global assessment of ATF3 peak localization relative to transcription start sites revealed that ATF3 was specifically enriched at promoter regions of genes (Fig. 5b) . Consistent with our findings that HDL treatment resulted in reduced production of proinflammatory cytokines, our ChIP-seq analysis demonstrated specific ATF3 binding at the promoters of genes encoding IL-6, IL-12p40 and TNF in the presence of HDL or HDL plus CpG, but not CpG alone (Fig. 5c) . We observed no enrichment of ATF3 at promoters of the non-HDLregulated cytokines that we identified in vivo ( Supplementary  Fig. 1a ) such as IL-18 and IL-13 ( Supplementary Fig. 4a) . Together these data demonstrate that after induction by HDL, ATF3 is specifically enriched at the promoters of cytokines found to be regulated by HDL both in vivo and in vitro, strongly suggesting that the antiinflammatory effects of HDL are mediated via this mechanism.
Functions of HDL are most intimately associated with processes related to atherosclerosis. Thus, we next examined whether ATF3 was induced after HDL treatment in an animal model of atherosclerosis. We examined the livers of atherosclerosis-prone Apoe-deficient mice fed a high-fat diet and observed that HDL-injected mice displayed significantly greater hepatic Atf3 mRNA expression compared with PBSinjected control mice (Fig. 5d) . Induction of ATF3 correlated with a substantial reduction in the levels of the direct ATF3 target genes encoding IL-6, IL-12p40 and cholesterol 25-hydroxylase (Ch25h) (Fig. 5e) . Notably, in the livers of HDL-injected Apoe-deficient mice, we observed a significant (P = 0.0092, unpaired two-tailed Student's t test) induction of Atf3 mRNA in Kupffer cells, whereas hepatocytes showed tenfold less expression (Supplementary Fig. 4b ). These data demonstrate that in an animal model of atherosclerosis, HDL induces the expression of ATF3 in macrophages, which may repress expression of inflammatory target genes.
HDL's anti-inflammatory effects are mediated via ATF3
To further assess the role of ATF3 in mediating the anti-inflammatory effects of HDL, we performed genome-wide transcriptome analysis on wild-type and Atf3-deficient BMDMs pretreated with HDL and subsequently stimulated with CpG or Pam 3 CSK 4 . Using the model presented in Figure 6a , we observed that ATF3 deficiency affected a large set of TLR-driven, HDL-modulated genes (224 probes detecting 188 genes; Supplementary Table 2a) . Transcripts induced or repressed in wildtype BMDMs by CpG or Pam 3 CSK 4 alone and counter-regulated by pretreatment with HDL were no longer modified in the absence of ATF3 (Fig. 6b, Supplementary Fig. 5a and Supplementary Table 2b-e). We observed substantially overlapping gene sets when CpG or Pam 3 CSK 4 stimulation was used (Supplementary Fig. 5b) . Furthermore, GOEA network visualization of TLR-regulated genes demonstrated that immune response-related functions modified by HDL were ATF3-dependent, whereas lipid metabolism terms were ATF3-independent (Supplementary Fig. 5c ). In fact, the majority of genes in the cholesterol biosynthesis pathway showed ATF3-independent regulation by HDL (Supplementary Fig. 5d ). Accordingly, we did not detect differential gene expression between wild-type and Atf3-deficient BMDMs for Srebf2 (ref. 26) or Nr1h3 (gene encoding LXR) target genes 27 (data not shown), indicating that ATF3 is not involved in their regulation in response to HDL. Of the genes we identified to be regulated by HDL and CpG in wild-type cells but not in Atf3-deficient cells (n = 130 genes), ~20% were confirmed as direct ATF3 target genes (n = 27 genes) by ChIP-seq, and analysis of GO terms of these direct ATF3 targets identified specific enrichment of genes involved in inflammatory processes (Supplementary Fig. 5e ).
To confirm that ATF3 was required for HDL-mediated inhibition of TLR-induced cytokine secretion, we compared the effects of pretreatment with HDL on subsequent TLR responses in wild-type and Atf3-deficient BMDMs. As expected, HDL significantly reduced CpGinduced production of IL-6 and IL-12p40 in wild-type BMDMs but not in Atf3-deficient BMDMs (Fig. 7a) . Additionally, we assessed the relevance of ATF3 induction by HDL in vivo by comparing wild-type and Atf3-deficient mice subjected to inflammation and liver injury induced by injection of CpG. HDL was no longer protective against CpG-induced liver damage in Atf3-deficient mice, as observed by comparable amounts of ALT release from Atf3-deficient mice injected with or without HDL (Fig. 7b) . Accordingly, unlike wild-type mice, Atf3-deficient mice injected with HDL showed no significant reductions in serum concentration of IL-12p40 and TNF or in hepatic TNF protein expression in response to CpG (Fig. 7b) . These data demonstrate that repression of proinflammatory cytokine responses by HDL both in vitro and in vivo is mediated by the induction of ATF3.
The protective functions of HDL are best documented in the context of atherosclerosis. Cardiovascular risk factors including hypertension, toxins from cigarette smoke, high blood sugar and turbulent blood flow can lead to localized and recurrent endothelial damage, a process thought to be critical in atherogenesis 28 . Endothelial damage is followed by an inflammatory response of macrophages that modulates the rate and extent of re-endothelialization 29, 30 . As HDL is known to accelerate vascular wound healing and re-endothelialization 31-33 , we next assessed whether ATF3 is also critical for the protective function of HDL in an atherosclerosis-relevant model of vascular repair. Whereas HDL effectively increased the amount of re-endothelialization after carotid artery injury in wild-type mice, we observed no change in Atf3-deficient mice (Fig. 7c,d ). These data suggest that HDL can dampen the local inflammation that occurs during vascular injury and that ATF3 thereby contributes to the vascular repair process. To broadly assess the effects of HDL in the vascular wall after injury, we performed transcriptional profiling of RNA isolated from the injured carotid artery segments from wild-type and Atf3-deficient mice that were injected with HDL or PBS. Hierarchical clustering of genes and samples showed that the replicate samples in the four groups clustered as four individual groups (Supplementary Fig. 6a ). HDL treatment strongly modulated genes in wild-type samples but not in Atf3-deficient samples, implying that the effects of HDL treatment were dependent on the presence of ATF3 (Supplementary Fig. 6a ). We next characterized the genes regulated by HDL and ATF3 in carotid artery samples and overlapped them with those genes earlier identified as regulated by HDL via ATF3 in macrophages in vitro ( Fig. 6 and Supplementary Fig. 5 ). We performed GOEA analysis with these genes and visualized the changes of GO terms resulting from treatment with HDL in wild-type but not ATF3-deficient samples using Biological Networks Gene Ontology tool (BINGO). Consistent with our in vitro macrophage analysis, treatment with HDL led to an ATF3-dependent reduction of the inflammatory responses in carotid artery samples (Supplementary Fig. 6b ). We validated these approaches using gene set enrichment analysis (GSEA) on the macrophage-carotid injury overlapping gene set. GSEA ranks RNA expression results based on their correlation with the phenotype and significant (FDR < 0.001, P < 0.001, empirical phenotype-based permutation test procedure) enrichment. These analyses revealed a highly significant enrichment of these ATF3 target gene sets in HDLtreated samples from wild-type mice but not Atf3-deficient mice (Fig. 7e) . These data indicate that the beneficial effects of HDL on carotid artery re-endothelialization are for the most part driven by ATF3 and the reduction of macrophage inflammation.
DISCUSSION
Epidemiological studies have consistently documented that low concentrations of HDL cholesterol in the blood represent a strong, independent risk factor for cardiovascular disease. The protective effect of HDL in cardiovascular and possibly other inflammatory diseases is thought to be the result of several beneficial functions. HDL relieves cells from excessive amounts of cholesterol, has strong antioxidative effects, inhibits platelet aggregation and exerts several vasoprotective effects 34 . Most notably, HDL also has the remarkable ability to modulate the inflammatory response in various cell types. HDL isolated from healthy individuals or reconstituted from purified ApoA1 and phospholipids is strongly anti-inflammatory. However, during an acute phase response or in chronic inflammatory states, HDL can be modified to become dysfunctional 33 .
The mechanisms by which HDL reduces inflammatory responses, particularly in macrophages, are not well understood. Although it is known that HDL can sequester LPS and thereby prevent cellular activation through TLR4, this mechanism does not explain why HDL can block a broad spectrum of TLR-mediated inflammatory responses in macrophages. In contrast to the current understanding that HDL can impair TLR signaling by interfering with amounts of raft cholesterol, we found that TLR signaling and subsequent nuclear translocation of the proinflammatory transcription factor NF-κB remained unaffected by HDL. We identified that the induction of ATF3, a key transcriptional modulator of innate immune response genes, is the main mechanism by which HDL mediates its anti-inflammatory activities in macrophages. ATF3 can be induced by TLR activation and acts as part of an important negative-feedback loop to limit TLR-driven inflammatory responses in macrophages. Hence, by inducing ATF3, HDL uses an ancient regulatory feedback system and can broadly and directly modify the inflammatory response of macrophages toward TLR stimulation. . Gene set enrichment analysis using the macrophage-carotid injury overlapping gene set applied to the carotid injury dataset assessing gene enrichment in HDL-treated samples derived from WT versus Atf3-deficient mice (e). Data are combined from three independent experiments (a; mean ± s.e.m, WT versus Atf3 −/− , unpaired two-tailed Student's t test, *P < 0.05, **P < 0.01), are from a single experiment (b; each symbol represents an individual mouse and horizontal lines indicate the mean; CpG versus HDL + CpG (per genotype), unpaired two-tailed Student's t test; *P < 0.05, ***P < 0.001), are from a single experiment (c; mean + s.e.m., PBS versus HDL (per genotype), unpaired two-tailed Student's t test; **P < 0.01), representative of each group in each genotype (d), and of three pooled biological replicates (injured carotid arteries from three individual mice) per condition, generated for a single microarray experiment (e).
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This discovery has broad implications as TLR activation triggers macrophage responses that contribute to a large number of inflammatory pathologies. For example, targeted deletion of TLRs or components of their signaling pathways in mice confers protection against atherosclerosis [35] [36] [37] . Furthermore, TLR-inducible proinflammatory cytokines such as IL-6, IL-12p40 and TNF all contribute to development of atherosclerosis 38 . Of note, ATF3 can also directly regulate cholesterol metabolism pathways by repressing expression of Ch25h, an enzyme required for 25-hydroxycholesterol-mediated formation of foam cells. Indeed, mice deficient in both ATF3 and ApoE have enhanced atherosclerotic lesions, which has been attributed to increased expression of Ch25h (ref. 39) . Consistently, we observed that injection of HDL in Apoe-deficient mice induced ATF3 expression and reduced the expression of Ch25h as well as of the proinflammatory cytokines IL-6 and IL-12p40. Hence, HDL appears to modulate both foam-cell formation and inflammation via ATF3, which could contribute to HDL's protective nature in atherosclerosis. However, HDL is known to exert other effects that can beneficially influence atherosclerosis that are likely independent of ATF3. For example, HDL's antioxidative function can prevent oxidation of LDL, which itself contributes to atherogenesis 17 . Modulation of cellular cholesterol by HDL may also affect antigen presentation and the induction of an adaptive immune response 16 . Furthermore, HDL reverses hyperproliferation of hematopoietic stem cell precursors, which can exaggerate atherosclerosis 40 . Similarly, HDL affects the activation of platelets, which do not have a nucleus 41 , and it reduces the integrin-mediated adhesion of leukocytes too quickly to involve transcription 42 . Therefore, the contribution of ATF3 to HDL's protective effects against atherosclerosis in vivo may be difficult to separate from the rest of its protective functions.
Our ChIP-seq analysis in macrophages, and RNA profiling studies in macrophages and injured carotid arteries revealed that HDL regulates an exceptionally broad set of target genes via ATF3 under normocholesterolemic conditions. This could be explained by the ability of ATF3 to recruit corepressors such as histone deacetylase 1 (HDAC1). Recruitment of HDAC1 by ATF3 is thought to result in less histone acetylation at target gene promoters, which is typically associated with a closed chromatin and inactivation of genes 3, 39 . Thus, via this mechanism, HDL could influence epigenetic modification of target genes. Indeed, we observed that ATF3 was constitutively bound across target gene promoters in resting macrophages, which was lost upon stimulation with CpG, consistent with transcriptional activation of these genes. However, HDL treatment further increased ATF3 binding across the genome, presumably remodeling chromatin structure to prevent transcriptional activation of these genes. These results provide a long-sought mechanistic link between HDL and its anti-inflammatory function.
Although the protective role of HDL is most well characterized in atherosclerosis, the capability of HDL to broadly modulate TLR responses suggests that HDL may be beneficial in other chronic inflammatory diseases. Our findings raise the possibility of using HDL-based therapeutics in treating inflammatory disorders not directly linked to hypercholesterolemia. Furthermore, our results imply that fine-tuning the negative regulators of inflammation, such as ATF3, may provide a therapeutic avenue for the treatment of a range of inflammatory pathologies.
METHODS
Methods and any associated references are available in the online version of the paper.
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